Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cellectar Biosciences long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Cellectar Biosciences Long Term Debt 2010-2025 | CLRB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cellectar Biosciences long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$227.2B
Boston Scientific (BSX)	$140.7B
Stryker (SYK)	$132.3B
EssilorLuxottica (ESLOY)	$128.4B
Medtronic (MDT)	$105.9B
Lonza Group Ag (LZAGY)	$47.4B
Haleon (HLN)	$46.2B
ResMed (RMD)	$31.3B
Agilent Technologies (A)	$29.2B
GE HealthCare Technologies (GEHC)	$28.6B
Terumo (TRUMY)	$28.2B
Koninklijke Philips (PHG)	$22.2B
Zimmer Biomet Holdings (ZBH)	$19.4B
Insulet (PODD)	$17.3B
Baxter (BAX)	$14.8B
Smith & Nephew SNATS (SNN)	$11.4B
Sunny Optical Technology (SNPTF)	$7.6B
Lantheus Holdings (LNTH)	$6.9B
Bio-Rad Laboratories (BIO)	$6.7B
Demant (WILYY)	$6.6B
Prestige Consumer Healthcare (PBH)	$4B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Perrigo (PRGO)	$3.5B
ICU Medical (ICUI)	$3.4B
Haemonetics (HAE)	$2.9B
Envista Holdings (NVST)	$2.6B
GN Store Nord (GNNDY)	$2.2B
LeMaitre Vascular (LMAT)	$1.9B
QuidelOrtho (QDEL)	$1.7B
AtriCure (ATRC)	$1.6B